PhRMA sues Trump administration over Medicare drug price pilot program
The pharmaceutical industry trade group PhRMA has filed a lawsuit against the Trump administration regarding a new Medicare drug pricing initiative.
Lawsuit challenges statutory authority
PhRMA argues that the most-favored nation pilot program exceeds the legal limits of Medicare Part B. The industry group claims this mandatory approach violates existing statutes governing federal health benefits. Officials in the administration are currently developing plans to temporarily sell certain restricted peptides while health officials finalize new rules.
Voluntary deals remain separate
The trade group accepts voluntary agreements with companies but opposes the mandatory GLOBE program. The administration exempted almost all companies from the pilot in exchange for their agreement to charge Medicaid prices voluntarily. This exemption means the lawsuit is unlikely to change current market conditions significantly.
Precedent concerns drive action
Industry leaders want to stop this program before it sets a dangerous legal precedent. They believe the voluntary deals are acceptable while the mandatory structure is not. The case highlights ongoing frustration among biotech firms regarding tariff issues and federal pricing policies.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.